Dendritic cells and immunotherapy for cancer

被引：15

作者：

Chang, DH

Dhodapkar, MV

机构：

[1] Mem Sloan Kettering Canc Ctr, Hematol Serv, New York, NY 10021 USA

[2] Rockefeller Univ, Lab Tumour Immunol & Immunotherapy, New York, NY 10021 USA

来源：

INTERNATIONAL JOURNAL OF HEMATOLOGY | 2003年 / 77卷 / 05期

关键词：

tumor vaccine; T-cells; immunotherapy; antigen presentation; dendritic cells;

D O I：

10.1007/BF02986611

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Dendritic cells, nature's adjuvant, are antigen-presenting cells specialized to initiate and regulate immunity. Their potent antigen-presenting function has encouraged targeting of dendritic cells (DCs) for harnessing the immune system against cancer. DCs are efficient at activating not only CD4(+) helper T-cells and CD8(+) killer T-cells but also B-cells and innate effectors such as natural killer and natural killer T-cells. Early studies of adoptive transfer of tumor antigen-loaded DCs have shown promise. However, DC vaccination is at an early stage, and several parameters still need to be established. The complexity of the DC system brings about the necessity for its rational manipulation for achieving protective and therapeutic immunity in patients. (C) 2003 The Japanese Society of Hematology.

引用

页码：439 / 443

页数：5

共 55 条

[41]

Morse MA, 1999, CANCER RES, V59, P56

[42] Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. [J].